Experimental Medicine Lovastatin and a Parent-Implemented Language Intervention for tratment of Fragile X Syndrome

Enter your info and the study team will contact you soon!
Your data is securely stored and only shared with the research team
Data is not saved in preview.
"Study drug and behavioral therapy treatment that may improve learning in Fragile X syndrome children"
Age:
10 to 17 years old
Gender:
Any
Healthy Volunteers:
No
Keywords:
fragile X syndrome, genetic disease, drug
Type:
Drug study, Phase 4
Investigator:
Description
This study looks at the effectiveness of a drug and behavioral treatment comprised of experimental medicine lovastatin or placebo, and the Parent-implemented Language Intervention (PILI) in children with Fragile X Syndrome. Children will receive either drug or placebo with all participating in the PILI. At the end of the study we will measure improvements in spoken language and behavior among lovastatin-treated compared to placebo treated children.
This study requires
Medical History
Questionnaires and interviews
Vital Signs
Physical
Blood/urine tests
IQ test
Autism assessment
Language assessments
Neurological exam
Parent and child tasks
Medication diary
Three visits
Who can participate?
Inclusion Criteria:

- Documentation of a full mutation with absence or deficient FMRP levels.

- Males and females ages 10 through 17 years

- Willingness of potential study participant as well as a parent or caretaker to participate in the protocol.

- Speech is the primary means of communication with three-word or longer utterances used on a daily basis.

- IQ ≤70 as measured by the Leiter- R.

- Sexually active women of childbearing potential (WCBP) must be using a medically acceptable method of birth control and have a negative qualitative serum β-human chorionic growth hormone (β-HCG) or urine pregnancy test collected at the initial screening visit.


Exclusion Criteria:

- Persons who do not speak English.

- Changes in any medications (including investigational medications) within the last month (4 weeks). All concomitant medications must have been on a stable course for at least 4 weeks prior to enrollment into the study and maintain stability throughout the course of the study.

- Changes in behavioral therapy or educational programming during the study. This does not include scheduled school holidays.

- Have any disease or condition (medical or surgical) at screening that might compromise the hematologic, cardiovascular, pulmonary, renal, gastrointestinal, or hepatic systems; or other conditions that might interfere with the absorption, distribution, metabolism, or excretion of the investigational product, or would place the subject at increased risk.

- Patients who, in the opinion of the investigator, are unsuitable in any other way to participate in this study, including being unable to comply with the requirements of the study or displaying clinically significant abnormalities in safety assessments at screening.

- Patients on prohibited medications

- History of recurrent status epilepticus.

- Inability to withhold grapefruit and grapefruit juice from diet during the entire clinical trial.

- Subjects unwilling to abstain from alcoholic beverages during the trial.

- Subjects who are actively suicidal.
Resources
Schedule
Study duration and period
5 months
Recruitment period
From Nov. 25, 2013
Location
UC Davis MIND Institute
2825 50th Street
Sacramento, CA 95817
Research Topic
Conditions:
  • Fragile X Syndrome
  • Genetic Diseases

Have any questions or want to learn more? Leave your contact details below and the research team will reach out to you.


Sending

Send SMS with Study Info:

SMS Sent!

Share Study Info via Email:


E-mail Preview